HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration

Tuebingen, Germany, April 15, 2025, HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a €21.5 million financing round with the addition of Wellington Partners to its investor syndicate. HepaRegeniX plans to use the proceeds to complete its ongoing Phase Ib trial and to advance the Phase IIa clinical trial for HRX-215, the company's lead clinical candidate in liver regeneration.

"We continue to make significant progress in the clinical evaluation of our lead candidate, HRX-215, and the additional investment is a strong acknowledgment of our achievements and the impressive safety results of HRX-215 in the completed Phase I trials," said Elias Papatheodorou, Chief Executive Officer at HepaRegeniX. "HepaRegeniX has brought to light the significant therapeutic potential of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) in multiple indications of high medical need, and we remain committed to making a real difference in the lives of patients that need liver resections due to tumors, for patients in need of a liver transplant, and for patients with ...